Radezolid

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Radezolid
Skeletal formula of radezolid
Systematic (IUPAC) name
N-{[(5S)-3-(2-fluoro-4′-{[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
Clinical data
Legal status
  • Investigational
Routes Intravenous infusion, oral
Identifiers
CAS number 869884-78-6
ATC code None
PubChem CID 11224409
ChemSpider 9399462
UNII 53PC6LO35W YesY
ChEMBL CHEMBL455461
Chemical data
Formula C22H23FN6O3 
Mol. mass 438.455 g/mol

Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).

References[edit]

External links[edit]